Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Dear Editor, Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) that primarily involves the megakaryocytic lineage, and is characterized by increased numbers of large, mature megakaryocytes in bone marrow as well as sustained thrombocytosis. Mutations in JAK2 or calreticulin (CALR) are present in about 50% and 25% of patients with ET, respectively, and these mutations are thought to drive MPN [1]. CALR and JAK2 mutations are mutually exclusive in MPNs [1]. Compared with patients with JAK2-mutated ET, patients with CALR-mutated ET have lower Hb levels and lower numbers of granulocytes, but higher numbers of platelets [2-6]. The CALR-mutated patients also have a lower incidence of thrombosis during their clinical course. Genetic background such as race may influence the risk of thrombosis, and recent study reported that Japanese ET patients with JAK2 mutation had a higher cumulative incidence of thrombosis than those with CALR mutations, although the differences were not significant [6]. Therefore, we analyzed the impact of JAK2 and CALR mutations on clinical features and thrombotic events in Japanese patients with ET.
Abstract
Dear Editor, Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) that primarily involves the megakaryocytic lineage, and is characterized by increased numbers of large, mature megakaryocytes in bone marrow as well as sustained thrombocytosis. Mutations in JAK2 or calreticulin (CALR) are present in about 50% and 25% of patients with ET, respectively, and these mutations are thought to drive MPN [1]. CALR and JAK2 mutations are mutually exclusive in MPNs [1]. Compared with patients with JAK2-mutated ET, patients with CALR-mutated ET have lower Hb levels and lower numbers of granulocytes, but higher numbers of platelets [2-6]. The CALR-mutated patients also have a lower incidence of thrombosis during their clinical course. Genetic background such as race may influence the risk of thrombosis, and recent study reported that Japanese ET patients with JAK2 mutation had a higher cumulative incidence of thrombosis than those with CALR mutations, although the differences were not significant [6]. Therefore, we analyzed the impact of JAK2 and CALR mutations on clinical features and thrombotic events in Japanese patients with ET.
참고문헌 (10)
- Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)
- Rotunno G, "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia", Blood, 123, pp.1552~1555 (2014)
- Rumi E, "JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes", Blood, 123, pp.1544~1551 (2014)
- Chen CC, "Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia", Ann Hematol, 93, pp.2029~2036 (2014)
- 박상혁, "Incidence, Clinical Features, and Prognostic Impact of CALR Exon 9 Mutations in Essential Thrombocythemia and Primary Myelofibrosis: An Experience of a Single Tertiary Hospital in Korea", Annals of Laboratory Medicine, 35(2), pp.233~237 (2015), 대한진단검사의학회
- Okabe M, "Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L", K mutations, 2016, pp.40, 68~76
- Swerdlow SH, "WHO classification of tumors of haematopoietic and lymphoid tissues" (2008), IARC
- Jaffe ES, "Pathology and genetics of tumors of haematopoietic and lymphoid tissues" (2001), IARC
- Chachoua I, "Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants", Blood, 127, pp.1325~1335 (2016)
- Carobbio A, "Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients", Blood, 117, pp.5857~5859 (2011)